These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 11783700

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
    Lopez H, Stepanik D, Vilches V, Scarano S, Sarachian B, Mikaelian G, Finlay J, Sucari A.
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
    [Abstract] [Full Text] [Related]

  • 5. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
    Blondeau JM, Hansen G, Metzler KL, Borsos S, Irvine LB, Blanco L.
    Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
    [Abstract] [Full Text] [Related]

  • 6. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
    Yamaguchi K, Miyazaki S, Kashitani F, Iwata M, Kanda M, Tsujio Y, Okada J, Tazawa Y, Watanabe N, Uehara N, Igari J, Oguri T, Kaimori M, Kawamura C, Iinuma Y, Nisawataira T, Tashiro H, Ueno K, Ishigo S, Yasujima M, Kawahara S, Itoh C, Yoshida T, Yamanaka K, Toyoshima S, Katoh J, Kudoh M, Matsushima T, Niki Y, Miyashita N, Funato T, Kaku M, Sato N, Saito Y, Ishii K, Kuwabara M, Hongo T, Negayama K, Kamihira S, Miyazaki Y, Takii M, Ishii M, Nakagawa K, Ono J, Takada T, Murakami N, Taira M, Tamaki I, Matsudou Y, Nakasone I.
    Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV, Ho DH, LeBlanc B, Streeter H, Dvorak T.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
    Evans ME.
    Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
    Yong DE, Cheong HJ, Kim YS, Park YJ, Kim WJ, Woo JH, Lee KW, Kang MW, Choo YS.
    J Korean Med Sci; 2002 Dec; 17(6):737-42. PubMed ID: 12482994
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.
    Marchese A, Debbia EA, Schito GC.
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():11-5. PubMed ID: 10997594
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of gemifloxacin.
    King A, May J, French G, Phillips I.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
    Tanaka M, Tunoe H, Mochida O, Kanayama A, Saika T, Kobayashi I, Naito S.
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):109-13. PubMed ID: 11035242
    [Abstract] [Full Text] [Related]

  • 16. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP, Prenna M, Mingoia M, Ripa S, Varaldo PE.
    Chemotherapy; 1998 Oct; 44(2):85-93. PubMed ID: 9551237
    [Abstract] [Full Text] [Related]

  • 17. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT, Counts C, Lody C, Carter O, Dodson S, Ojha N.
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
    Rolston KV, Frisbee-Hume S, LeBlanc BM, Streeter H, Ho DH.
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):187-94. PubMed ID: 12458127
    [Abstract] [Full Text] [Related]

  • 19. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA, Qadri SM, Ueno Y, Walters EA, Domenico P.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [Abstract] [Full Text] [Related]

  • 20. A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group.
    Hoban DJ, Bouchillon SK, Karlowsky JA, Johnson JL, Butler DL, Miller LA, Poupard JA.
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3008-11. PubMed ID: 11036014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.